论文部分内容阅读
心痛定(Nifedipine)是一个钙通道阻滞剂,在美国已将它推荐为抗心绞痛药。关于该药的药代动力学尚缺乏报导,本文报告了作者对该药的药代动力学和生物利用度的研究,结果提示:由于个体差异。固定的用药剂量使某些病人不能达到有效血浆药物浓度,可能是治疗失败的原因。
Nifedipine is a calcium channel blocker that has been recommended as an anti-anginal drug in the United States. Pharmacokinetics of the drug is still lacking, and the authors report on the pharmacokinetics and bioavailability of the drug. The results suggest that: Due to individual differences. A fixed dose that prevents some patients from achieving effective plasma drug concentrations may be responsible for the failure of treatment.